key: cord-1005258-f9jr9kki
authors: Shan, D.; Johnson, J. M.; Fernandes, S. C.; Mendes, M.; Suib, H.; Holdridge, M.; Burke, E. M.; Beauregard, K. G.; Zhang, Y.; Cleary, M.; Xu, S.; Yao, X.; Patel, P. P.; Plavina, T.; Wilson, D. H.; Chang, L.; Kaiser, K. M.; Natterman, J.; Schmidt, S. V.; Latz, E.; Hrusovsky, K.; Mattoon, D.; Ball, A. J.
title: SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity.
date: 2020-08-17
journal: nan
DOI: 10.1101/2020.08.14.20175356
sha: 7a069d606ef94f6added5d1fb1f14c7cb2087aa2
doc_id: 1005258
cord_uid: f9jr9kki

The COVID-19 pandemic continues to have an unprecedented impact on societies and economies worldwide. Despite rapid advances in diagnostic test development and scale-up, there remains an ongoing need for SARS-CoV-2 tests which are highly sensitive, specific, minimally invasive, cost-effective and scalable for broad testing and surveillance. Here we report development of a highly sensitive single molecule array (Simoa) immunoassay on the automated HD-X platform for the detection of SARS-CoV-2 Nucleocapsid protein (N-protein) in venous and capillary blood (fingerstick). In pre-pandemic and clinical sample sets, the assay has 100% specificity and 97.4% sensitivity for serum / plasma samples. The limit of detection (LoD) estimated by titration of inactivated SARS-CoV-2 virus is 0.2 pg/ml, corresponding to 0.05 Median Tissue Culture Infectious Dose (TCID50) per ml, > 2000 times more sensitive than current EUA approved antigen tests. No cross-reactivity to other common respiratory viruses, including hCoV229E, hCoVOC43, hCoVNL63, Influenza A or Influenza B, was observed. We detected elevated N-protein concentrations in symptomatic, asymptomatic, and pre-symptomatic PCR+ individuals using capillary blood from a finger-stick collection device. The Simoa SARS-CoV-2 N-protein assay has the potential to detect COVID-19 infection via antigen in blood with similar or better performance characteristics of molecular tests, while also enabling at home and point of care sample collection.

Median Tissue Culture Infectious Dose (TCID50) per ml, > 2000 times more sensitive than current EUA approved antigen tests. No cross-reactivity to other common respiratory viruses, including hCoV229E, hCoVOC43, hCoVNL63, Influenza A or Influenza B, was observed. We detected elevated N-protein concentrations in symptomatic, asymptomatic, and pre-symptomatic PCR+ individuals using capillary blood from a finger-stick collection device. The Simoa SARS-CoV-2 N-protein assay has the potential to detect COVID-19 infection via antigen in blood with performance characteristics similar to or better than molecular tests, while also enabling at home and point of care sample collection.

In November 2019, the SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) emerged in Wuhan, China and since has caused a worldwide pandemic 1 . To date, the USFDA has granted Emergency Use Authorization (EUA) to three types of SARS-CoV-2 assays: molecular testing or PCR, antibody testing or serology, and antigen testing 2 . Molecular testing for viral RNA is the primary diagnostic modality for active infection, while serology measures anti-SARS-CoV2 antibodies post-infection 3, 4 . Although RT-PCRbased molecular testing for viral RNA in respiratory specimens is the primary diagnostic tool for active infection, concerns have been raised about the risk of false negative results associated with the use of nasal and nasopharyngeal swabs 5 . This is especially true in the days before symptom onset; Kucirka et al. have found the probability of a false negative result in an infected person to decrease from 100% on day 1 post-infection to 67% on day 4. On day 5, the median time for symptoms to appear, molecular tests still had a 38% probability of producing a false negative result and declined no further than 20% in the days that followed, when the infection should be most detectable 6 . Furthermore, the complexity, cost, supply chain challenges, and relatively lower throughput of RT-PCR results are disadvantages toward fulfilling large-scale testing required to enable societies to re-open 7 .

Antigen detection by immunoassay has the potential advantages of a simpler workflow, faster turnaround time, lower cost, and with a supply chain diversified from PCR. However, currently available antigen tests are generally less sensitive than PCR, for example one lateral flow assay has been reported to have percent positive agreement (PPA) with qRT-PCR of only 24 to 30% 8, 9 . Two EUA cleared antigen tests have claimed sample types of nasopharyngeal or nasal swabs with 96.7% and 84% PPA with PCR and should greatly enhance diagnostic capacity, but they are still subject to the same sampling challenges associated with nasal or nasopharyngeal swabs and less analytical sensitivity relative to PCR 10, 11 . SARS-CoV-2 infections can present unusual peripheral symptoms, such as stroke, heart attack, kidney damage, neurological symptoms, and COVID-toe. These clinical manifestations suggest that this respiratory virus can migrate from the lungs into the bloodstream. Mehra et al. first described evidence of SARS-CoV-2 peripheral involvement during post-mortem histological examination of effected tissues, including electron microscopy images of viral inclusion structures in endothelial cells 12 . It was hypothesized that SARS-CoV-2 infection may facilitate the induction of endothelitis in multiple organs as a direct consequence of viral involvement. Wölfel et al. reported that SARS-Cov-2 virus was not detectable in blood using molecular diagnostic techniques 13 , but additional later studies have found evidence that plasma viremia may play a significant role in disease course and that viral loads in plasma may predict risk of death 14 .

Recently, Ogata et al. measured SARS-CoV-2 antigens (S1 antigen, spike antigen, N-protein) in venous blood for the first time 15 . They hypothesized that detection of viral antigen could be used to stratify patients between mild and severe cases, but that asymptomatic or mild cases would not have measurable levels. If true, this would be a distinct difference between SARS-CoV-2 and SARS-CoV, as patients of the latter had measurable levels of N-protein in blood up to 3 weeks after symptom onset, and measurement of N-protein had 94% PPA up to 5 days compared to PCR 16 .

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint

We theorized that by leveraging the exceptional sensitivity of Single Molecule Array (Simoa) immunoassay technology, we could detect and quantitate SARS-CoV-2 antigen directly in serum and plasma from venous collection and capillary blood acquired by commercially available finger-stick collection devices. Here we report the development of a blood-based assay for SARS-CoV-2 N-protein that potentially shows detection of clinically significant viral loads in active and pre-symptomatic COVID-19 infections, avoiding the use of swabs and the need to sample nasopharyngeal or nasal fluids. and microbial specimens for cross-reactivity testing were obtained from ZeptoMetrix.

(zeptometrix.com).

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint Assay Development. In Research Use Only (RUO) products Single Molecule Array (Simoa) technology offers sensitivity on average 1000-fold greater than traditional immunoassays 17, 18 . In brief, the technology involves performing a paramagnetic microbead-based sandwich ELISA, followed by isolation of individual capture beads in arrays of femtoliter-sized reaction wells. Singulation of capture beads within microwells permits buildup of fluorescent product from an enzyme label, so that signal from a single immunocomplex can be detected with a CCD camera in 30 seconds. At very low analyte concentrations, Poisson statistics dictate that bead-containing microwells in the array will contain either a single labeled analyte molecule or no analyte molecules, resulting in a digital signal of either "active" or "inactive" wells. Data collection involves counting active wells corresponding to single enzyme labels. At higher analyte concentrations, digital measurements transition to analog measurements of total fluorescence intensity. Simoa data are reported as Average Enzymes per Bead (AEB). It is widely used in the field of neurodegenerative disease and recently, for the measurement of SARS-CoV-2-associated biomarkers 19, 20 . It has also been demonstrated to rival the sensitivity of PCR for monitoring HIV infection through measurement of the p24 capsid protein in blood 21, 22 .

SARS-CoV-2 N-protein Assay. Antibodies and antigens were obtained from commercial sources. Eight different antibodies and five antigens were screened, resulting in more than 60 different test configurations. The antibody and antigen combination that produced the best signal / background ratio for both calibrator and positive samples was selected. Diluent formulations, detector antibody and Streptavidin-β-Galactosidase concentrations were then optimized, as well as assay protocols (2-step vs 3-step; incubation times). A phosphate-based sample diluent was selected with EDTA to inhibit proteases, heterophilic blocker and a detergent to help de-envelope and inactivate virus particles.

Assay. An assay was developed to monitor the serological response of IgG to the full-spike of SARS-CoV-2. This assay has been submitted for EUA clearance (USFDA application EUA20164);

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint verification and validation details are planned to be released in product-specific validation reports and instructions for use upon product launch.

Assay Verification. N-protein Assay. The assay was verified by testing 6 runs over 3 days over 2 lots, for a combined total of 12 runs. Verified characteristics include precision, ad-mixture linearity, spike recovery, limit of blank (LoB), limit of detection (LoD), and limit of quantification (LoQ) for serum, K2 EDTA plasma, and dried blood spots (Supplementary Figure S1 and Table S1 ). Precision was determined using 2 diluent-based controls and 3 matrix based spiked samples. Limit of detection (LoD) was determined with gamma-inactivated SARS-CoV-2 virus diluted 6e6 fold into a serum from a negative donor, using stock with a TCID50 of 2.8e5 per mL (final TCID50 = 0.05 per mL), and testing 36 replicates over 3 days and 2 different assay lots. Admixture linearity was demonstrated using negative matrix spiked with heatinactivated virus, and then mixed in varying ratios with a separate non-spiked matrix to create ten levels.

We established a preliminary clinical cutoff by measuring N-protein levels in four SARS-CoV-2 negative cohorts: 1) pre-pandemic serum / plasma (N=100); 2) a panel of plasma samples sero-negative for SARS-CoV-2 negative and sero-positive for common respiratory infections (N=36, Supplementary Table S2) Sample Types. Serum, K2EDTA plasma, and dried blood spots were used in the analyses. Serum and plasma were collected by normal processing methods, and stored frozen at -80C before analysis. Serum and plasma samples were diluted 4-fold into assay diluent on the HD-X instrument before measurement.

Dried blood spots (DBS) were collected using Mitra collection kits from Neoteryx according to standard protocols (https://www.neoteryx.com/home-blood-blood-collection-kits-dried-capillary-blood). Tips absorb 20 µl of whole blood and are then allowed to dry for at least 16 hours in a pouch with dessicant.

Tips are extracted into 250 µl of assay diluent with shaking at 400 rpm overnight at 2 -8℃, resulting in a . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint 12.5-fold sample dilution. All sample results have been corrected for dilution factors, to represent the concentration within the sample matrix.

To correlate serum and plasma matrices, matched samples from PCR+ donors

were measured with the N-Protein assay. N-protein levels correlated between matrices with a slope of 1.12 and an R 2 of 0.995 (Supplementary Figure S3) . To verify the recovery of N-protein from the Mitra tips, whole blood was collected into K2EDTA tubes, spiked with recombinant N-protein, and then processed into either plasma or DBS. N-protein levels were measured in both sample types. N-protein levels correlate between matrices with R 2 = 0.993 and a slope of 1.97. The concentration in DBS was approximately ½ of that in plasma, as expected due to the excluded volume of hematocrit which is separated from plasma (Supplementary Figure S4 ).

immunoglobulins plays a role in the decrease of N-protein signal, samples were treated with 10 mM DTT at 37°C for 15 minutes. To demonstrate the effectiveness of this treatment the following experiment was conducted: 1) negative serum was spiked with N-protein and measured on the N-protein assay; 2) a 500x concentration of anti-N-protein antibody was added and the sample was measured, resulting in a 60% decrease in antigen; 3) the sample spiked with both antigen and antibody was treated with DTT according to the protocol above and measured, resulting in a 75% rescue of antigen signal (Supplementary Figure   S5 ).

Cross reactivity studies. Cultured and inactivated pathogens were spiked into negative serum samples to attain 10 5 TCID50 per ml, using a minimum of 4x dilution of viral stock into serum. Some virus cultures had insufficiently high stock titer to achieve 10 5 TCID50 per ml, and these viruses were tested at the highest titer possible after a 4x dilution into serum. No cross-reactivity was observed, as detailed in Supplementary Table S4. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint

To determine the clinical utility of the N-protein assay for serum and plasma, we measured PCR+ samples from BocaBio and the University of Bonn, and pre-pandemic samples from BioIVT. Figure 1 panel A represents only "first-draw" samples, in which every data point represents a unique donor. This use-case is appropriate for a test that is intended to screen novel patients as positive or negative 23 . Our preliminary cutoff of 0.9 pg/mL (dashed line) confers a clinical sensitivity of 97.6% (37/38 positives >0.9 pg/ml) and clinical specificity of 100% (100/100 negatives < 0.9 pg/ml). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint blood samples within days 1-5, 6-10 and 11-20 of symptom onset 16 . Our data shows similar performance, albeit with enhanced sensitivity, notably after the 1 st week of infection. This suggests the possibility that an ultrasensitive antigen assay could expand the diagnostic window beyond that addressable by the current EUA approved antigen assays that claim clinical sensitivity only within the first 5 to 7 days after onset of symptoms 10, 11 . To determine this, future studies will need to test a sample cohort with welldefined clinical characteristics, in which the onset of infection and symptom are accurately known.

We also measured anti-SAR-CoV-2 specific IgG in the longitudinal samples from the U. Bonn cohort ( Figure   2 ). N-protein concentration in plasma was observed to decrease over time with a concurrent increase in anti-SARS-CoV2 IgG levels. By normalizing patient responses and using a four-parameter logistic regression to the average response, we find N-protein clearance to occur at 15.6 days and IgG plateau at 7.7 days after hospitalization. Several of these patients had already undergone seroconversion prior to first collection; given that seroconversion for SARS-CoV-2 can occur between day 7 to 13 postsymptom 15,24 , we estimate that N-protein clearance occurs between days 22 to 28 and IgG plateau between days 14-20 post-symptom, similar to timelines observed for SARS 16 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint we hypothesize that antigen-masking plays a negligible role, and that instead N-protein levels decrease due to clearance from the blood. To allow at-home or point-of-care collection of blood samples, we tested dried blood spots (DBS) collected with Mitra® tips (Neoteryx.com). These devices absorb 20 µl of capillary blood from a finger-stick, and users may subsequently store and ship them without cold-chain requirements. We measured N-protein .

CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint levels in DBS patient samples collected in the presence of active COVID-19 infections using the Mitra devices (CTCH cohort). This long-term care facility has established a practice of testing residents and staff for COVID-19 weekly using an authorized molecular test. This enabled a comparison of the performance of the Simoa SARS-CoV-2 N-Protein Assay against the gold-standard of PCR in the context of active and on-going COVID-19 infections; relative days of collection are shown in Table 1 . In Figure 3 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint False negative PCR results represent a significant challenge in the COVID-19 pandemic 5 . Kucirka et al.

report the highest probability of PCR false-negative results before symptom onset, with the false-negative rate decreasing from 100% to 67% in the first four days post-infection. On day 5, the median time for symptom-onset, the probability of a false negative result in a PCR-based molecular test was still 38% 6, 26 .

Compounding the problem of poor clinical discrimination in pre-symptomatic patients, He et al. observed the highest viral load in throat swabs at time of symptom onset, and inferred that infectiousness will peak at or before symptom onset 25 . In this context, the ability of the Simoa SARS-CoV-2 N-Protein assay to detect pre-symptomatic individuals could be particularly important. In the CTCH cohort, 8 of the 14 PCR+ donors presented without symptoms even with elevated levels of Nprotein and in Figure 3 panel B, we separated donors into four groups: PCR-; asymptomatic PCR+ that did not show symptoms at any point during infection; pre-symptomatic PCR+ that did not show symptoms at the first collection but developed symptoms by the second collection; and symptomatic PCR+ that . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint presented with symptoms at the first collection. Fully asymptomatic donors have a lower median level of N-protein; however, we do not see different levels of N-protein between pre-symptomatic or symptomatic donors. Ogata et al. suggested that viral antigen would only present in blood in severe or late-stage cases, however our data suggest that some mechanism exists for viral antigen to transfer to blood even in early and asymptomatic cases 15 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint

In Figure 4 panel B, we have grouped donors into recovered (n=4) and not recovered (n=2) and display Nprotein and IgG levels for both collections. Average N-protein level decreases 10-fold (1143 to 98 pg/ml) for recovered donors across both collection dates, contrasted with a higher starting average and more moderate decrease of 2-fold (2287 to 988 pg/ml) for not recovered donors. We measured low IgG levels for all donors at collection 1, suggesting that seroconversion had not yet occurred. At collection 2 we detected a slight IgG increase for some donors, but a large increase only for donor 1. This donor also had a concomitant, large decrease in N-protein, and was the only donor with high N-protein levels to recover by the 2 nd collection. Serological assessment may complement the N-protein assay and help stratify outcomes of severe cases. All data for the CTCH cohort is shown in Supplementary Table S5 .

In summary, we have developed a blood-based assay for SARS-CoV-2 N-Protein and our studies demonstrate detection of clinically significant viral loads in active, pre-symptomatic and asymptomatic COVID-19 infections, using sample collection methods that avoid swabs and the need to sample nasopharyngeal or nasal fluids. Based on testing performed to date, we estimate a clinical sensitivity of 97.4% in serum / plasma using two PCR+ cohorts and clinical specificity of 100% using a cohort of 100 prepandemic samples. We see no cross-reactivity to other common respiratory viruses, including hCoV229E, hCoVOC43, hCoVNL63, Influenza A or Influenza B. Using titers of gamma-inactivated virus we estimate the limit of detection (LoD) of our assay to be 0.05 TCID50, > 2000 times more sensitive than current antigen tests with EUA approval for use in nasal swabs 10, 11 .

We have demonstrated detection in capillary blood using the Neoteryx Mitra® dried blood spot (DBS) collection device, which enables at-home and point-of-care sample collection. Using DBS samples, we successfully monitored disease status of staff and residents in the presence of active COVID-19 infections with clinical sensitivity comparable to molecular testing in our preliminary experiments. Higher . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint concentrations of N-protein associated with increased disease severity and mortality, and vice-versa clearance of the antigen associated with greater recoverability.

We plan further studies to validate the ability of the SARS-CoV-2 N-Protein assay to diagnose COVID-19 and determine if it has comparable or better sensitivity than molecular testing, including studies with larger, prospective cohorts with better characterized clinical symptoms and timelines. In particular, we will attempt to conduct trials with well-defined onset of infection to determine the window of effectiveness of the SARS-CoV-2 N-Protein assay, which may be able to diagnose both earlier than molecular testing (pre-symptomatic infection) and later than current EUA cleared antigen tests (beyond one week post-symptom).

The SARS-CoV-2 antigen assay has the potential to be available for widespread deployment through minimally invasive remote and home sample collection and utilization of the fully automated HD-X immunoassay platform. It is expected that this SARS-CoV-2 product candidate antigen assay may provide a new, orthogonal method for early detection of SARS-CoV-2 infection that can significantly and rapidly augment the accuracy and availability of the SARS-CoV-2 testing arsenal. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint Supplemental Information. Figure S1 . Calibration curve of the Simoa SARS-CoV-2 N Protein Advantage Assay. Lower limit of quantitation (LLoQ) is shown as the dashed line, and calibrator concentrations are denoted on graph. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint Figure S2 . Seven sample cohorts were used to establish a preliminary clinical cutoff of 0.9 pg/ml for the SARS-CoV-2 N-Protein assay; sample numbers are shown as N in the axis label. JN +ve was K2 EDTA plasma from PCR+ donors from the U. Bonn cohort. BocaBio (+ve) were PCR+ serum from that commercial supplier. CT Care Home +ve (PCR+) and -ve (PCR-) were dried blood spot (DBS) samples from residents and staff of the care facility. Pre-pandemic samples were a mixture of serum and K2 EDTA plasma from donors acquired before December 2019 purchased from BioIVT. Respiratory Panel was K2 EDTA plasma purchased from BioIVT and from donors serologically confirmed to have been infected with combinations of H. influenza, RSV, influenza A, influenza B, parainfluenza (1-4), adenovirus, enterovirus, M. pneumoniae, Legionella, B. pertussis, and C. pneumoniae. Coronavirus Panel was serum purchased from BioIVT from donors serologically confirmed to have been infected with human coronaviruses-HKU, OC43, 229E and NL63. Preliminary cutoff of 0.9 pg/ml was chosen to confer 100% specificity over all SARS-CoV-2 negative sample cohorts. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint Figure S5 . A DTT reduction protocol was established to unmask N-protein bound by antibody in serum by doing a control experiment with recombinant antigen and capture antibody spiked into sample matrix. N-protein concentration measured in serum was reduced after co-spiking with antibody, indicative of epitope masking. Adding DTT to the sample rescued 63% of the signal loss, indicating that this treatment could unmask antigen in seroconverted samples.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint Table S2 . Serum from COVID-19-negative donors serologically confirmed to have been infected with common respiratory viruses, demonstrating no cross-reactivity.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 17, 2020. . https://doi.org/10.1101/2020.08.14.20175356 doi: medRxiv preprint

COVID-19)

Food & Drug Administration

A serological assay to detect SARS-CoV-2 seroconversion in humans

Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients. medRxiv : the preprint server for health sciences

False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications

Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure

The COVID-19 testing debacle

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital

BD Veritor System for Rapid Detection of SARS-CoV-2

Endothelial cell infection and endotheliitis in COVID-19

Virological assessment of hospitalized patients with COVID-2019

SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality

Serial Profiling of SARS-CoV-2 Antigens and Antibodies in COVID-19 Patient Plasma

Nucleocapsid protein as early diagnostic marker for SARS

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19

Simple diffusion-constrained immunoassay for p24 protein with the sensitivity of nucleic acid amplification for detecting acute HIV infection

Fully Automated Digital Immunoassay for p24 Protein with the Sensitivity of Nucleic Acid Amplification for Detecting Acute HIV Infection

Food & Drug Administration. Antigen Template for Manufacturers

Antibody responses to SARS-CoV-2 in patients with COVID-19

Temporal dynamics in viral shedding and transmissibility of COVID-19

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application